Besides, the vaccine was 83.7 percent effective against moderate-to-severe cases in the trial, and in particular, 81.7 percent effective against those moderate-to-severe cases caused by Delta, the report said.
BEIJING, Sept. 25 (Xinhua) — A new COVID-19 vaccine developed by China’s Clover Biopharmaceuticals has proven to be 67 percent effective against COVID-19, and 79 percent against the Delta variant in a mass clinical trial, Reuters reported recently.…